Drug Profile
Eliglustat - Sanofi
Alternative Names: Cerdelga; Eliglustat; Eliglustat tartrate; Genz-112638; GZ 385660Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator University of Michigan
- Developer Sanofi
- Class 2 ring heterocyclic compounds; Amides; Pyrrolidines; Small molecules
- Mechanism of Action Glucosylceramide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gaucher's disease type I
- Phase III Gaucher's disease type III
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for clinical-Phase-Unknown development in Gaucher's disease type III(Combination therapy, In adolescents, In children, In the elderly, In adults) in Taiwan (PO, Capsule)
- 16 Aug 2022 Launched for Gaucher's disease type I in Japan (PO)
- 28 Oct 2021 Sanofi announces intention to submit regulatory application for Gaucher's disease type I (In children) in 2025